Lynnet Koh, MS, MBA
Chairman / CEO
Lynnet Koh is a serially successful, award-winning entrepreneur who founded Targazyme with the commitment to transform cancer treatment with innovative cancer immunotherapies aimed at curing cancer without the toxic side effects of standard-of-care cancer therapies. Under her leadership, the company has achieved significant milestones, including the development of potential mega blockbuster Phase 3 ready drug candidates and game-changing immune cell therapies with the potential to address critical unmet medical needs for the treatment of late-stage cancer patients with solid cancer tumors. Lynnet’s major achievements with leading Targazyme from concept to positive human proof of concept outcomes in phase 2 clinical trials, FDA phase 3 Special Protocol Assessment award, multiple game-changing products delivering multiple shots on goal with transforming cancer patient outcomes, and a significant patent portfolio worldwide. With a track record of pioneering major technological breakthroughs that have transformed people’s lives worldwide and created over $126B+ new product revenues throughout her career, she has had a profound impact on global communication, connectivity, and cancer patient outcomes. Lynnet holds a Master of Science Degree from MIT and remains committed to bringing transformative therapies to cancer patients worldwide and making cancer history.